Open AccessElevated indoleamine-2,3-dioxygenase enzyme activity in a novel mouse model of HIV-associated atherosclerosis
Author(s) -
Alison Kearns,
Stephani Velasquez,
Fengming Liu,
Sheng Dai,
Yong Chen,
Gabrielle Lehmicke,
Jennifer Gordon,
Jay Rappaport,
Xuebin Qin
Publication year - 2019
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000002255
Subject(s) - kynurenine , indoleamine 2,3 dioxygenase , kynurenine pathway , cart , apolipoprotein e , pathogenesis , immunology , medicine , inflammation , endocrinology , tryptophan , disease , biology , biochemistry , amino acid , mechanical engineering , engineering
HIV atherosclerosis and cardiovascular disease (CVD) represent a significant human health burden in the era of combination antiretroviral therapy (cART). The pathogenesis of HIV atherosclerosis is still poorly understood, due, in part, to the lack of a suitable small animal model. Indoleamine-2,3-dioxygenase (IDO) enzyme activity is the first and rate-limiting step in tryptophan catabolism and is measured by the kynurenine to tryptophan ratio (KTR). The serum KTR is a biomarker of inflammation and has recently been implicated as an important risk factor for CVD in patients living with HIV (PLWH) who are virologically suppressed under cART. However, IDO activity in HIV-associated CVD has not been studied in mouse model before.